Novo Integrated Sciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OTC.Pink
Novo Integrated Sciences has withdrawn a proposal for potential share issuance due to its delisting from the Nasdaq Capital Market, while still proceeding with other key proposals at its upcoming annual meeting.
OTC.Pink
Novo Integrated Sciences' CEO, Robert Mattacchione, has resigned effective February 5, 2025, but will remain as Chairman of the Board and Chairman of a subsidiary.
OTC.Pink
DEF 14A: Novo Integrated Sciences Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting
Novo Integrated Sciences is holding a virtual annual meeting on November 22, 2024, seeking stockholder approval for director elections, a potential stock issuance, a reverse stock split, and auditor ratification.